<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397394</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-085</org_study_id>
    <nct_id>NCT03397394</nct_id>
  </id_info>
  <brief_title>Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ATLAS study is to determine how patients with locally advanced or
      metastatic urothelial carcinoma respond to treatment with rucaparib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years and 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related Adverse Events (AEs) as assessed by CTCAE v4.03 as a measure of safety and tolerability</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years and 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious AEs as a measure of safety and tolerability</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years and 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with worsening laboratory values as a measure of safety and tolerability</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years and 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma PK (Cmin) of rucaparib based on sparse sampling</measure>
    <time_frame>From enrollment to primary completion of study (up to approximately 2 years and 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Metastatic Urothelial Carcinoma</condition>
  <condition>Renal Pelvis Carcinoma</condition>
  <condition>Ureter Carcinoma</condition>
  <condition>Urinary Bladder Carcinoma</condition>
  <condition>Urethra Carcinoma</condition>
  <condition>Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Rucaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral rucaparib (monotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Rucaparib will be administered daily.</description>
    <arm_group_label>Rucaparib</arm_group_label>
    <other_name>CO-338</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically or cytologically confirmed locally advanced or metastatic
             transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder
             or urethra)

          -  Received 1 or 2 prior standard of care regimens for advanced or metastatic disease

          -  Confirmed radiologic disease progression during or following recent treatment

          -  Mandatory biopsy is required during screening

          -  Measurable disease per RECIST v1.1

          -  Adequate organ function

          -  ECOG 0 or 1

        Exclusion Criteria:

          -  Prior treatment with a PARP inhibitor

          -  Symptomatic and/or untreated CNS metastases

          -  Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption
             of rucaparib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
    <phone>1-855-262-3040 (USA)</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
    <phone>1-303-625-5160 (non-USA)</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint John's Health Center - John Wayne Cancer Institute (JWCI)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
    </contact>
    <contact_backup>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology &amp; Oncology Associates (ECHO)</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada (CCCN)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Urology Clinics</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Oncology &amp; Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
    </contact>
    <contact_backup>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia, Emily Couric Clinical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clovis Oncology Clinical Trial Navigation</last_name>
    </contact>
    <contact_backup>
      <phone>855-262-3040</phone>
      <email>clovistrials@emergingmed.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibitor</keyword>
  <keyword>PARPi</keyword>
  <keyword>HRD</keyword>
  <keyword>ATLAS</keyword>
  <keyword>homologous recombination</keyword>
  <keyword>DNA repair</keyword>
  <keyword>LOH</keyword>
  <keyword>DNA defect</keyword>
  <keyword>DNA anomaly</keyword>
  <keyword>Rucaparib</keyword>
  <keyword>MIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

